Request a visit from a Besins Healthcare Representative
Watch video Educational Series
Request your Oestrogel Patient pad
Request your Oestrogel demonstration pump-pack (contains placebo gel)
Feedback survey

Oestrogel is an oestrogen-only treatment indicated for1: 

  • Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women 

  • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. 

The experience treating women older than 65 years is limited.

Oestrogel is a body identical transdermal oestrogen gel for every day use that comes in a pump-pack for convenient dose dispensing.1,2

  • is an easy to use, clear colourless oestrogen gel1,3
  • is a body identical transdermal gel containing estradiol1,2
  • is identical to the oestrogen produced by the body1,2
  • Oestrogel is the number 1 dispensed oestrogen in the UK4
  • is the only oestrogen gel available in a pump-pack offering individualisation of treatment by enabling dose tailoring (from 2 to 4 pump actuations a day) compared to fixed dose combined HRT preparations1,25

Oestrogel is the only HRT gel indicated for secondary prevention of osteoporosis in postmenopausal women.1,26

How to use video

Reduces the vasomotor symptoms of menopause27

In a double blind, randomised, placebo-controlled study (n=221) Oestrogel has been shown to significantly reduce the mean daily frequency and severity of hot flushes, at week 12, compared to placebo (p<0.001)5,27

1
mean reduction in the frequency of moderate to severe hot flushes from baseline vs placebo at 57% (p<0.001)27*

* at 12 weeks on starting dose

1
mean reduction in severity of hot flushes from baseline vs placebo at 23% (p<0.001)5,27*

* at 12 weeks on starting dose

OESTROGEL was shown to be as effective as oral oestrogen and transdermal oestrogen patches at relieving vasomotor symptoms28-30

Secondary prevention of osteoporosis

  • Oestrogel is the only HRT gel indicated for secondary prevention of osteoporosis in postmenopausal women1,26
  • Bone mineral density (BMD) declines rapidly during the early menopausal years.31 The annual rate of loss is:31
  • These rates are associated with approximately 50–100% higher fracture rates31
  • Approximately 40% of all postmenopausal women will eventually experience fractures31

Dosing

Oestrogel is easy to use3

The usual starting dose is 2 pumps (2.5g gel containing 1.5mg estradiol) once daily.1
  • After one month, if required, this can be increased to a maximum of 4 pumps (5g gel containing 3.0mg estradiol) daily.1
  • Two pumps will provide effective relief for most women, but the dose can easily be tailored if necessary, up to a maximum of four metered doses (5g gel; 3mg estradiol)1
  • Oestrogel is easy to use and gentle on the skin3
  • Oestrogel should be administered daily on a continuous basis.1

66%

of Oestrogel patients are on the minimum dose of Oestrogel, which is 2 pumps a day.3

How to use Oestrogel1

The patient should apply the gel to a large area (at least 750cm2) of clean, dry skin on the arms, shoulders or mid-inner thighs. Oestrogel should NOT be applied on or near the breasts or on the vulval region. A frequent change in application sites is recommended2

Patients should be informed that others, especially children, should not come in contact with the area of the body where gel has been applied on.
This product is flammable until dry.

The video below explains how to apply Oestrogel.
Please accept marketing-cookies to watch this video.
Please refer to the Oestrogel SmPC and Package Leaflet for full application instructions

In a survey we asked Oestrogel patients how satisfied are they with the following features of the Oestrogel pump-pack3:

95%

95% very / fairly satisfied with ease of use3

92%

92% very / fairly satisfied with how well Oestrogel fits into their daily life3

84%

84% very/fairly satisfied with how effective Oestrogel is in reducing their menopause symptoms3

References:

1. Oestrogel Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/353/smpc Last accessed: March 2023.

2. Panay N, Post Reprod Health 2014;20(2):69-72.

3. Data on file OES/2021/016.

4. Data on File BHUK/2023/074

5. Archer DF, et al. Menopause 2003;10(6):516–521.

26. Sandrena Gel Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/1048/smpc Last accessed: March 2023.

27. Archer DF, et al. Menopause 2012;19(6):622-629.

28. Dupont A, et al. Maturitas 1991;13:297–311.

29. Jensen PB, et al. Maturitas 1987;9:207–215.

30. Akhila V, Pratapkumar. Int J Fertil Womens Med 2006;51(2):64-69.

31. Finkelstein JS, et al. J Clin Endocrinol Metab 2008;93(3):861–868.